SEC Form 4 · accession 0001591747-26-000002
Disc Medicine, Inc. · IRON
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kevin Bitterman
Director
Period of report
Sep 1, 2026
Accepted (ET)
Sep 3, 2026 · 5:43 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001816736
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Sep 1, 2026 | S | 70 | $79.95 | D | 349,140 | I | See footnote |
| Common StockF3 | Sep 1, 2026 | S | 58 | $79.95 | D | 337,427 | I | See footnote |
| Common StockF4 | Sep 1, 2026 | S | 1 | $79.95 | D | 14,012 | I | See footnote |
| Common StockF5,F2 | Sep 2, 2026 | S | 26,542 | $80.17 | D | 322,598 | I | See footnote |
| Common StockF5,F3 | Sep 2, 2026 | S | 22,090 | $80.17 | D | 315,337 | I | See footnote |
| Common StockF5,F4 | Sep 2, 2026 | S | 511 | $80.17 | D | 13,501 | I | See footnote |
| Common StockF6,F2 | Sep 2, 2026 | S | 10 | $80.98 | D | 322,588 | I | See footnote |
| Common StockF6,F3 | Sep 2, 2026 | S | 9 | $80.98 | D | 315,328 | I | See footnote |
| Common StockF6,F4 | Sep 2, 2026 | S | 2 | $80.98 | D | 13,499 | I | See footnote |
| Common StockF7,F2 | Sep 3, 2026 | S | 2,810 | $79.98 | D | 319,778 | I | See footnote |
| Common StockF7,F3 | Sep 3, 2026 | S | 2,339 | $79.98 | D | 312,989 | I | See footnote |
| Common StockF7,F4 | Sep 3, 2026 | S | 54 | $79.98 | D | 13,445 | I | See footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares were sold pursuant to a Rule 10b5-1 trading plan adopted on July 30, 2026.
- F2These shares are held by Atlas Venture Opportunity Fund I, L.P. ("Opportunity I"). The general partner of Opportunity I is Atlas Venture Associates Opportunity I, L.P. ("Associates I"). Atlas Venture Associates Opportunity I, LLC ("Associates I LLC") is the general partner of Associates I. The Reporting Person is a member of Associates I LLC and disclaims beneficial ownership of such securities held by Opportunity I, except to the extent of his pecuniary interest therein, if any.
- F3These shares are held by Atlas Venture Opportunity Fund II, L.P. ("Opportunity II"). The general partner of Opportunity II is Atlas Venture Associates Opportunity II, L.P. ("Associates II"). Atlas Venture Associates Opportunity II, LLC ("Associates II LLC") is the general partner of Associates II. The Reporting Person is a member of Associates II LLC and disclaims beneficial ownership of such securities held by Opportunity II, except to the extent of his pecuniary interest therein, if any.
- F4These shares are held by Atlas Venture Fund XII, L.P. ("Atlas XII"). The general partner of Atlas XII is Atlas Venture Associates XII, L.P. ("Associates XII"). Atlas Venture Associates XII, LLC ("Associates XII LLC") is the general partner of Associates XII. The Reporting Person is a member of Associates XII LLC and disclaims beneficial ownership of such securities held by Atlas XII, except to the extent of his pecuniary interest therein, if any.
- F5The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.95 to $80.9421 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F6The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.9677 to $81.0079 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F7The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.95 to $80.28 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.